

Review

Epigenetic regulation in Autism spectrum disorder

Sraboni Chaudhury*

Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, MI-48109, USA

* **Correspondence:** Email: sraboni@med.umich.edu; Tel: +1-734-615-2995.

Abstract: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by an impaired social communication skill and often results in repetitive, stereotyped behavior which is observed in children during the first few years of life. Other characteristic of this disorder includes language disabilities, difficulties in sensory integration, lack of reciprocal interactions and in some cases, cognitive delays. One percentage of the general population is affected by ASD and is four times more common in boys than girls. There are hundreds of genes, which has been identified to be associated with ASD etiology. However it remains difficult to comprehend our understanding in defining the genetic architecture necessary for complete exposition of its pathophysiology. Seeing the complexity of the disease, it is important to adopt a multidisciplinary approach which should not only focus on the “genetics” of autism but also on epigenetics, transcriptomics, immune system disruption and environmental factors that could all impact the pathogenesis of the disease. As environmental factors also play a key role in regulating the trigger of ASD, the role of chromatin remodeling and DNA methylation has started to emerge. Such epigenetic modifications directly link molecular regulatory pathways and environmental factors, which might be able to explain some aspects of complex disorders like ASD. The present review will focus on the role of epigenetic regulation in defining the underlying cause for ASD.

Keywords: Autism; DNA methylation; histones; GABA; reelin

1. Introduction

Brain development is a complex plastic process which involves coordination of specific sets of gene expression in a temporal space. The autism spectrum disorders (ASD) are a heterogeneous group of neuro developmental disorders, which show impairment in several behavioral features such as in reciprocal social communication along with restricted and repetitive patterns of behaviors. In

addition, some specific sensory-motor behavioral phenotypes including indifference to pain/heat/cold, adverse response to specific sounds or textures, excessive sensation when smelling or touching objects, and fascination with lights or spinning objects are often referred to as the possible qualifying behavioral symptoms for a diagnosis of ASD [1-3]. Patients diagnosed with ASD also exhibit difficulties in integration of sensory modalities and alteration in motor control (for example, poor manual dexterity and coordination) [4-6]. It has been hypothesized that these abnormalities in sensory-motor modalities, which specifically affect the auditory pathway, could result in communication impairments thereby leading to autism [7-14]. Genetic studies have demonstrated that hundreds of genes may be involved in the pathogenesis of ASD [15-17]. Different genetic variants such as copy number variations, single-nucleotide polymorphisms and de novo mutations have been attributed to the etiology of ASD [18,19]. Altered linguistic style has been observed in ASD and there are number of genes which have been associated with it [20,21]. There are reports, which suggest that immune system plays an important role in the pathophysiology of autism. The altered levels of inflammatory markers, cytokines, and immunoglobulins have been found in brain tissues, cerebral spinal fluid, and in the sera of autistic patients in the autopsy [22]. Despite all of the information regarding genetic components associated with ASD, it is suggested that environmental factors may play a major role in the development of ASD. Within monozygotic twin pairs, there are notable differences for diagnosis and symptom severity in ASD [23]. In separate studies, the correlation for heritability of ASD among twin and sibling has moderate genetic component and a significantly larger environmental component [24]. Environmental factors such as maternal hospitalization due to viral infections during the first trimester of pregnancy and prenatal exposure to sodium valproate could be correlated to ASD occurrence [25,26]. Additional factors, such as drugs, pollutants and several xenobiotics are strongly attributed to ASD pathophysiology [27]. Therefore, one can hypothesize that the molecular changes that are involved in the development of ASD are likely to be regulated by mechanisms which are, in part, modulated by environmental cues. In this context, epigenetic mechanism, such as DNA methylation and histone modifications might provide a linkage between the environmental stimuli and gene expression altered in ASD [28-30]. Epigenetic regulation including DNA methylation, histone protein modifications, and microRNAs function regulate the transcriptional potential of a cell without altering its DNA sequence. The alteration in epigenetic marks is crucial during neurodevelopment and any disruption could lead to significant impacts on neurodevelopment and cognitive function [31-34]. Further, studies have revealed chromatin remodeling and mRNA translation are important biological pathways associated with ASD [35]. Thus, it is crucial to understand the role of epigenetic regulation in the pathophysiology and etiology of ASD.

2. Effect of DNA Methylation in ASD

DNA methylation is one of the most widely studied epigenetic modifications in neurodevelopment disorder including ASD. DNA methylation involves the covalent attachment of a methyl (CH₃) group to the cytosine of a CpG dinucleotide [36,37]. DNA methylation is known to be associated with transcriptional repression either via direct inhibition of transcription factor binding or the recruitment of methyl CpG binding domain (MBD) proteins, which interact with histone modifiers to converse a repressive chromatin state with the help of DNA methyltransferase (DNMT). DNMT1 functions mainly in maintenance of DNA methylation whereas DNMT3A and DNMT3B are predominantly in de novo DNA methylation [38]. However, the function of these enzymes are

very important as global deletion of mouse *Dnmt1*, *Dnmt3b*, or both *Dnmt3a* + *Dnmt3b* cause midgestation lethality (gestational day (GD) 9.5–11.5), while deletion of only *Dnmt3a* results in severe growth retardation and is lethal by 4 weeks of age [39-41]. It was found that in ASD, *GAD1* (glutamate decarboxylase 1) expression is likely regulated by epigenetic mechanisms including DNMT-mediated DNA hypermethylation and DNA demethylation, which is associated with the initial hydroxylation of 5-mC to form 5-hmC by members of the TET protein family [42]. These studies suggest that alteration in the enzymes catalyzing DNA methylation is critical for normal neurodevelopmental processes. Genetic and environmental variation, and an interaction between the two, can influence epigenetic change. Like genome wide studies, epigenome-wide association studies (EWAS) have been done to understand the epigenetic state in ASD [43-49]. Studies have shown that in ASD hypo methylated genes are often overexpressed. Further there is an inverse correlation between gene expression (*C1Q*, *C3*, *ITGB2* (*C3R*), *TNF- α* , *IRF8* and *SPI1*) and DNA methylation within the ASD individuals. These genes are involved in synaptic pruning and microglial cell specification [46]. In the same article it was observed that *HDAC4* was significantly overexpressed in autistic subjects and gene expression of *HDAC4* has complex relation with DNA methylation in the autistic brain especially in the cortical regions. Studies have shown that oxidative DNA lesions and an altered pattern of DNA methylation are important molecular features of the autism cerebellar phenotype. It is also demonstrated that DNA isolated from the cerebellum of BTBR *T+tf/J* mice and post-mortem cerebellum of individuals with autism, is characterized by an increased levels of 8-oxodeoxyguanosine, 5-methylcytosine, and 5-hydroxymethylcytosine [50]. The development of ASD has been long associated with increased paternal age. DNA methylation is responsible for errors during spermatogenesis and could help in explaining a potential cause of this phenomenon. DNA methylation in paternal sperm has been linked to an early risk for autism in children [51]. There are DNA-binding proteins with methyl-CpG binding domains (MBDs), known as the MBD protein family which are associated with DNA methylation. They act as transcriptional repressors by binding to 5mC and interact with many components. RTT (Rett Syndrome) is caused by mutation of methyl-CpG binding protein 2 (*MeCP2*) [52]. *MeCP2* is a nuclear protein that attaches to methylated DNA and regulates gene expression by transcription repression. Loss or mutation of *MeCP2* causes transcriptional deregulation and is characteristic of RTT. RTT subjects do have ASD like phenotypes. Also, patients with Fragile X syndrome have a characteristic physical appearance and impaired behavior with co-occurrence of ASD in 25% of male and 6% of female patients [53]. These studies suggest that DNA methylation plays an important role in the pathophysiology of ASD and related disorders.

3. Effect of chromatin remodeling in ASD

Chromatin remodeling is a dynamic process, which regulates the gene expression by altering condensed genomic DNA accessibility. Chromatin structure is influenced by posttranslational modifications on N-terminal tails of histone proteins. With the advancement in next-generation sequencing, the lists of histone modifiers that are mutated in human neurodevelopmental disorders have been identified in large number. In ASD large-scale exome sequencing, studies have highlighted the dysregulation of histone methylation to be one of the major factors [54,55]. Therefore, regulation of modified histone is very critical for the development and function of the central nervous system. Histone lysine methyltransferases which is the primary regulator of methylated H3K4 has been

shown to be mutated in ASD [56]. Studies have shown a reduction in the levels of H3K9me3 and increased acetylated H3K9 in the deficient MeCp2 mouse which is considered to be mouse model for Rett syndrome (that has ASD like phenotype) as well as in RTT patients [57]. Exposure to valproic acid (VPA) during pregnancy has been implicated in the etiology of children with ASD [58-61]. In rodents prenatal VPA exposure showed behavioral alterations similar to those observed in humans with autism [62,63]. Inhibiting HDACs is one of the likely mechanisms responsible for the VPA-induced ASD-like phenotype. The inhibition of histone deacetylation causes increased levels of acetylated histones along with changes in DNA methylation [64]. Both mechanisms act in a coordinated fashion to relax the chromatin states which finally results in promoting gene expression [65]. During embryonic brain development, VPA-mediated histone modifications which regulate genes associated with ASD are likely to be more vulnerable. On the other hand, postnatal exposure to VPA is shown to increase the expression of genes linked to the GABAergic phenotype in terminally differentiated neurons. It has been reported that in terminally differentiated neurons, VPA increases expression of GAD1 and REELIN [64,66], both of which have been implicated in the pathophysiology of ASD [67]. Studies have shown the implication of dysregulation of epigenetically modified genes including GABA receptor genes, and REELIN in ASD [68]. From all these studies it is clear that chromatin remodeling is an important feature that plays a differential role in various phase of brain development. Thus, understanding regulation of chromatin remodeling might be a crucial aspect in the etiology of ASD.

4. Conclusion

It has been observed that ASD is a complex syndrome with alteration in behavior as well as in structural and molecular changes in developing brain. It is evident that the alteration in various brain areas in ASD is due to ablation in various genes as well as several environmental factors. With the new insight of epigenetic regulation it is possible that alteration of genes might be induced by environmental factors via epigenetic modifications. There are several genes which are associated with ASD such as GAD67 (GAD1), Reelin, GABA β 3, Oxytocin receptor (OXTR), Brain-derived neurotrophic factor (BDNF), Ubiquitin–protein ligase E3A (UBE3A), Engrailed-2 (EN-2), SH3 and multiple ankyrin repeat domains (SHANK3). Additionally, it has also been shown that there is an abnormality in the methylated region of the UBE3A coding exons [69]. It was found that the action of these genes in ASD is mediated by either DNA methylation or chromatin remodeling. Therefore, more studies are required to understand the detail mechanism associated with different epigenetic regulation to identify more specific drug target for the complex disease like ASD.

Conflict of interest

The author declares no conflict of interest.

References

1. Kanner L (1944) Autistic disturbances of affective contact. *Nerv Child* 2: 217-250.
2. Asperger H (1944) Die "autistischen Psychopathen" im Kindesalter. *Arch Psychiatr Nervenkr* 177: 76-137.

3. Coleman M, Gillberg C (2012) *The Autisms*. Oxford University Press: USA 432 pp.
4. Foxe JJ, Molholm S, Del Bene VA, et al. (2013) Severe multisensory speech integration deficits in high-functioning school-aged children with autism spectrum disorder (ASD) and their resolution during early adolescence. *Cereb Cortex* 25: 298-312.
5. Marco EJ, Hinkley LB, Hill SS, et al. (2011) Sensory processing in autism: a review of neurophysiologic findings. *Pediatr Res* 69: 48-54.
6. Ming X, Brimacombe M, Wagner GC (2007) Prevalence of motor impairment in autism spectrum disorders. *Brain Dev* 29: 565-570.
7. Gillberg C, Steffenburg S, Jakobsson G (1987) Neurobiological findings in 20 relatively gifted children with Kanner-type autism or Asperger syndrome. *Dev Med Child Neurol* 29: 641-649.
8. Khalifa S, Bruneau N, Roge B, et al. (2001) Peripheral auditory asymmetry in infantile autism. *Eur J Neurosci* 13: 628-632.
9. Boddaert N, Belin P, Chabane N, et al. (2003) Perception of complex sounds: abnormal pattern of cortical activation in autism. *Am J Psychiatry* 160: 2057-2060.
10. Boddaert N, Chabane N, Belin P, et al. (2004) Perception of complex sounds in autism: abnormal auditory cortical processing in children. *Am J Psychiatry* 161: 2117-2120.
11. Rosenhall U, Nordin V, Brantberg K, et al. (2003) Autism and auditory brain stem responses. *Ear Hear* 24: 206-214.
12. Teder-Salejarvi WA, Pierce KL, Courchesne E, et al. (2005) Auditory spatial localization and attention deficits in autistic adults. *Brain Res Cogn Brain Res* 23: 221-234.
13. Gomot M, Belmonte MK, Bullmore ET, et al. (2008) Brain hyper-reactivity to auditory novel targets in children with high-functioning autism. *Brain* 131: 2479-2488.
14. Demopoulos C, Brandes-Aitken AN, Desai SS, et al. (2015) Shared and divergent auditory and tactile processing in children with autism and children with sensory processing dysfunction relative to typically developing peers. *J Int Neuropsychol Soc* 21: 444-454.
15. Huguet G, Ey E, Bourgeron T (2013) The genetic landscapes of autism spectrum disorders. *Annu Rev Genomics Hum Genet* 14: 191-213.
16. Jeste SS, Geschwind DH (2014) Disentangling the heterogeneity of autism spectrum disorder through genetic findings. *Nat Rev Neurol* 10: 74-81.
17. Bourgeron T (2015) From the genetic architecture to synaptic plasticity in autism spectrum disorders. *Nat Rev Neurosci* 16: 551-563.
18. Levitt P, State MW (2011) The conundrums of understanding genetic risks for autism spectrum disorders. *Nat Neurosci* 14: 1499-1506.
19. Rogers SJ, Ozonoff S (2005) Annotation: what do we know about sensory dysfunction in autism? A critical review of the empirical evidence. *J Child Psychol Psychiatry* 46: 1255-1268.
20. Benítez-Burraco A, Lattanzi W, Murphy E (2016) Language Impairments in ASD Resulting from a Failed Domestication of the Human Brain. *Front Neurosci* 10: 373.
21. Murphy E, Benítez-Burraco A (2016) Language deficits in schizophrenia and autism as related oscillatory connectopathies: An evolutionary account. *Neurosci Biobehav Rev*: 044198.
22. Cohly HH, Panja A (2005) Immunological findings in autism. *Int Rev Neurobiol* 71: 317-341.
23. Ronald A, Hoekstra RA (2011) Autism spectrum disorders and autistic traits: a decade of new twin studies. *Am J Med Genet B Neuropsychiatr Genet* 156: 255-274.
24. Torres A, Phillips J, Miller J, et al. (2011) Genetic heritability and shared environmental factors among twin pairs with autism. *Arch Gen Psychiatry* 68: 1095-1102.

25. Atladóttir HO, Thorsen P, Østergaard L, et al. (2010) Maternal infection requiring hospitalization during pregnancy and autism spectrum disorders. *J Autism Dev Disord* 40: 1423-1430.
26. Christensen J, Grønberg TK, Sørensen MJ, et al. (2013) Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. *JAMA* 309: 1696-1703.
27. LaSalle JM (2011) A genomic point-of-view on environmental factors influencing the human brain methylome. *Epigenetics* 6: 862-869.
28. Grafodatskaya D, Chung B, Szatmari P, et al. (2010) Autism spectrum disorders and epigenetics. *J Am Acad Child Adolesc Psychiatry* 49: 794-809.
29. Persico AM, Bourgeron T (2006) Searching for ways out of the autism maze: genetic, epigenetic and environmental clues. *Trends Neurosci* 29: 349-358.
30. Schanen NC (2006) Epigenetics of autism spectrum disorders. *Hum Mol Genet* 15: 138-150.
31. Hutnick LK, Golshani P, Namihira M, et al. (2009) DNA hypomethylation restricted to the murine forebrain induces cortical degeneration and impairs postnatal neuronal maturation. *Hum Mol Genet* 18: 2875-2888.
32. Feng S, Cokus SJ, Zhang X, et al. (2010) Conservation and divergence of methylation patterning in plants and animals. *Proc Natl Acad Sci U S A* 107: 8689-8694.
33. LaSalle JM (2013) Epigenomic strategies at the interface of genetic and environmental risk factors for autism. *J Hum Genet* 58: 396-401.
34. Millan MJ (2013) An epigenetic framework for neurodevelopmental disorders: from pathogenesis to potential therapy. *Neuropharmacology* 68: 72-82.
35. Ebert DH, Greenberg ME (2013) Activity-dependent neuronal signalling and autism spectrum disorder. *Nature* 493: 327-337.
36. Bestor TH, Tycko B (1996) Creation of genomic methylation patterns. *Nat Genet* 12: 363-367.
37. Bird A (2002) DNA methylation patterns and epigenetic memory. *Genes Dev* 16: 6-21.
38. Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 33: 245-254.
39. Li E, Bestor TH, Jaenisch R (1992) Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* 69: 915-926.
40. Lei H, Oh SP, Okano M, et al. (1996) De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. *Development* 122: 3195-3205.
41. Okano M, Bell DW, Haber DA, et al. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. *Cell* 99: 247-257.
42. Dong E, Gavin DP, Chen Y, et al. (2012) Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients. *Translational Psychiatry* 2: e159.
43. Berko ER, Suzuki M, Beren F, et al. (2014) Mosaic epigenetic dysregulation of ectodermal cells in autism spectrum disorder. *PLoS Genet* 10: e1004402.
44. Ginsberg MR, Rubin RA, Falcone T, et al. (2012) Brain transcriptional and epigenetic associations with autism. *PLoS One* 7: e44736.
45. Ladd-Acosta C, Hansen KD, Briem E, et al. (2014) Common DNA methylation alterations in multiple brain regions in autism. *Mol Psychiatry* 19: 862-871.
46. Nardone S, Sharan Sams D, Reuveni E, et al. (2014) DNA methylation analysis of the autistic brain reveals multiple dysregulate biological pathways. *Transl Psychiatry* 4: e433.

47. Nguyen A, Rauch TA, Pfeifer GP, et al. (2010) Global methylation profiling of lymphoblastoid cell lines reveals epigenetic contributions to autism spectrum disorders and a novel autism candidate gene, RORA, whose protein product is reduced in autistic brain. *FASEB J* 24: 3036-3051.
48. Wong CC, Meaburn EL, Ronald A, et al. (2014) Methylomic analysis of monozygotic twins discordant for autism spectrum disorder and related behavioural traits. *Mol Psychiatry* 19: 495-503.
49. Wang Y, Fang Y, Zhang F, et al. (2014) Hypermethylation of the enolase gene (ENO2) in autism. *Eur J Pediatr* 173:1233-1244.
50. Keil KP, Lein PJ (2016) DNA methylation: a mechanism linking environmental chemical exposures to risk of autism spectrum disorders? *Environ Epigenet* 2: pii: dvv012.
51. Feinberg JI, Bakulski KM, Jaffe AE, et al. (2015) Paternal sperm DNA methylation associated with early signs of autism risk in an autism-enriched cohort. *Int J Epidemiol* 44: 1199-1210.
52. Amir RE, Van den Veyver IB, Wan M, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 23: 185-188.
53. Hatton DD, Sideris J, Skinner M, et al. (2006) Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. *Am J Med Genet* 140: 1804-1813.
54. Iossifov I, O'roak BJ, Sanders SJ, et al. (2014) The contribution of de novo coding mutations to autism spectrum disorder. *Nature* 515: 216-221.
55. De Rubeis S, He X, Goldberg AP, et al. (2014) Synaptic, transcriptional and chromatin genes disrupted in autism. *Nature* 515: 209-215.
56. Vallianatos CN, Iwase S (2015) Disrupted intricacy of histone H3K4 methylation in neurodevelopmental disorders. *Epigenomics* 7: 503-519.
57. Thatcher KN, LaSalle JM (2006) Dynamic changes in Histone H3 lysine 9 acetylation localization patterns during neuronal maturation require MeCP2. *Epigenetics* 1: 24-31.
58. Christianson AL, Chester N, Kromberg JG (1994) Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs. *Dev Med Child Neurol* 36: 361-369.
59. Williams PG, Hersh JH (1997) A male with fetal valproate syndrome and autism. *Dev Med Child Neurol* 39: 632-634.
60. Williams G, King J, Cunningham M, et al. (2001) Fetal valproate syndrome and autism: additional evidence of an association. *Dev Med Child Neurol* 43: 202-206.
61. Moore S, Turnpenny P, Quinn A, et al. (2000) A clinical study of 57 children with fetal anticonvulsant syndromes. *J Med Genet* 37: 489-497.
62. Tomasz Schneider RP (2004) Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. *Neuropsychopharmacol* 30: 80-89.
63. Wagner GC, Reuhl KR, Cheh M, et al. (2006) A new neurobehavioral model of autism in mice: pre-and postnatal exposure to sodium valproate. *J Autism Dev Disord* 36: 779-793.
64. Guidotti A, Dong E, Kundakovic M, et al. (2009). Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. *Trends Pharmacol Sci* 30: 55-60.
65. Kundakovic M, Chen Y, Guidotti A, et al. (2009) The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. *Mol Pharmacol* 75: 342-354.
66. Tremolizzo L, Doueiri MS, Dong E, et al. (2005) Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. *Biol Psychiatry* 57: 500-509.

-
67. Zhubi A, Chen Y, Dong E, et al. (2014) Increased binding of MeCP2 to the GAD1 and RELN promoters may be mediated by an enrichment of 5-hmC in autism spectrum disorder (ASD) cerebellum. *Transl Psychiatry* 4: e349.
 68. Flashner BM, Russo ME, Boileau JE, et al. (2013) Epigenetic factors and autism spectrum disorders. *Neuromolecular Med* 15: 339-350.
 69. Jiang YH, Sahoo T, Michaelis RC, et al. (2004) A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. *Am J Med Genet A* 131: 1-10.



AIMS Press

© 2016 Sraboni Chaudhury licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)